Fractyl’s Revita DMR System commercially available in Germany
Fractyl Health has announced the commercial availability of its Revita DMR System in Germany, an endoscopic procedural therapy that is...
Fractyl’s Revita DMR System commercially available in Germany
Fractyl initiates Erase T2DM task force to establish root cause mechanisms underlying T2DM
Fractyl Health reports latest Revita DMR outcomes for T2DM
Two-year Revita DMR outcomes show durability of procedure in diabetics
Fractyl’s pioneering Metabolic Balance Model identifies new model of intestine’s role in metabolism
Fractyl gains US$100 million financing to expand clinical development programs for T2DM
Revita DMR granted FDA Breakthrough Device Designation for T2DM
First patient enrolled in pivotal REVITA-T2Di study for T2DM
INSPIRE: Revita DMR plus GLP-1RA shows durable insulin-free glycaemic control